{Reference Type}: Journal Article
{Title}: Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy.
{Author}: Dheeraj A;Garcia Marques FJ;Tailor D;Bermudez A;Resendez A;Pandrala M;Grau B;Kumar P;Haley CB;Honkala A;Kujur P;Jeffrey SS;Pitteri S;Malhotra SV;
{Journal}: Cell Rep Med
{Volume}: 5
{Issue}: 5
{Year}: 2024 May 21
{Factor}: 16.988
{DOI}: 10.1016/j.xcrm.2024.101552
{Abstract}: Y-box binding protein-1 (YB-1) is a proto-oncogenic protein associated with protein translation regulation. It plays a crucial role in the development and progression of triple-negative breast cancer (TNBC). In this study, we describe a promising approach to inhibit YB-1 using SU056, a small-molecule inhibitor. SU056 physically interacts with YB-1 and reduces its expression, which helps to restrain the progression of TNBC. Proteome profiling analysis indicates that the inhibition of YB-1 by SU056 can alter the proteins that regulate protein translation, an essential process for cancer cell growth. Preclinical studies on human cells, mice, and patient-derived xenograft tumor models show the effectiveness of SU056. Moreover, toxicological studies have shown that SU056 treatment and dosing are well tolerated without any adverse effects. Overall, our study provides a strong foundation for the further development of SU056 as a potential treatment option for patients with TNBC by targeting YB-1.